ImmunityBio, Inc.

ImmunityBio, Inc. develops next‑generation cell and immunotherapy products that harness and amplify the innate and adaptive arms of the immune system to treat cancer and infectious diseases. Founded by Dr. Patrick Soon‑Shiong in 2014, the company leverages his pioneering work in protein nanoparticle therapeutics to design therapies that activate natural killer and T‑cell responses while building durable immunological memory. ImmunityBio’s pipeline includes fusion‑protein vaccines, on‑colytic viral platforms, and cell‑based treatments currently in clinical trials for solid tumors, hematologic malignancies, and COVID‑19. The company’s distinctive approach lies in reprogramming the patient’s own immune system to attack disease and create long‑term protection, positioning it at the forefront of oncology and infectious‑disease immunotherapy.